SCHEMBL4886489

SCHEMBL4886489

CCOC(=O)c1ccc2ncn(CCC(C)(C)N)c2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.43
ALDH1A1 P00352 4/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
TNF P01375 2/20 0.38
KDM4E B2RXH2 2/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
RECQL P46063 1/20 0.36
MAPK10 P53779 1/20 0.36
ADRA1A P35348 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
GABRA2 P47869 3/20 0.36
GABRB2 P47870 3/20 0.36
GAA P10253 2/20 0.36
USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23530019 0.84 CYP1A2 (0.50) CYP1A2ALDH1A1MAPTMEN1NPC1
SCHEMBL29549645 0.84 CYP1A2 (0.50) CYP1A2ALDH1A1MAPTMEN1NPC1
SCHEMBL4777107 0.82 TNF (0.36) ALDH1A1MAPTMEN1KMT2ATNF
SCHEMBL4893401 0.78 CNR2 (0.39) ALDH1A1MAPTMEN1NPC1RAB9A
SCHEMBL4889652 0.78 CNR2 (0.41) ALDH1A1MAPTMEN1NPC1RAB9A
SCHEMBL4916141 0.77 NPC1 (0.48) CYP1A2ALDH1A1MAPTMEN1NPC1
SCHEMBL4913399 0.76 NPC1 (0.47) MAPTMEN1NPC1RAB9AKMT2A
SCHEMBL29668753 0.74 CYP1A2 (0.40) CYP1A2ALDH1A1MAPTNPC1RAB9A
SCHEMBL25435833 0.74 CYP1A2 (0.40) CYP1A2ALDH1A1MAPTNPC1RAB9A
SCHEMBL30124865 0.74 CYP1A2 (0.40) CYP1A2ALDH1A1MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269281-A1 Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-10-30 US disclosed
US-20080269281-A1 Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-10-30 US disclosed
US-20080269281-A1 Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269281-A1 Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs ADRB3, ADRB2, ADRB1 CYP1A2 294/4885ALDH1A1 1087/4885MAPT 4073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.